| |
| |
|
| Insider
Information: |
Kewalramani Reshma |
| Relationship: |
Director |
| City: |
Boston |
| State: |
MA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
2 |
|
| Direct
Shares |
217,246 |
|
|
Indirect Shares
|
0 |
|
|
| Direct
Value |
$58,575,197 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
217,246 |
|
|
| Total
Value |
$58,575,197 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
1
|
0
|
|
Stock
price went up :
|
1
|
0
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
1.0
|
0.0
|
| Percentage
Gain/Loss : |
 23.1%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Vertex Pharmaceuticals Inc |
VRTX |
CEO & President, Direc... |
2024-02-23 |
136,507 |
2018-10-08 |
0 |
Premium* |
|
|
Ginkgo Bioworks Holdings, Inc |
DNA |
Director |
2022-09-30 |
80,739 |
2022-06-10 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
55 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 3
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| DNA |
Ginkgo Bioworks Holdings,... |
Director |
– • – |
2022-06-10 |
4 |
A |
$0.00 |
$0 |
D/D |
70,921 |
70,921 |
0 |
- |
|
| DNA |
Ginkgo Bioworks Holdings,... |
Director |
– • – |
2022-09-30 |
4 |
OE |
$0.00 |
$0 |
D/D |
9,818 |
80,739 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP and CMO |
• – – |
2018-10-08 |
4 |
AS |
$186.95 |
$430,920 |
D/D |
(2,305) |
1,909 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP and CMO |
• – – |
2019-02-06 |
4 |
A |
$0.00 |
$0 |
D/D |
13,315 |
15,224 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP and CMO |
• – – |
2019-02-19 |
4 |
AS |
$186.75 |
$278,163 |
D/D |
(1,488) |
13,736 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP and CMO |
• – – |
2019-05-15 |
4 |
AS |
$165.41 |
$39,864 |
D/D |
(241) |
13,736 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP and CMO |
• – – |
2019-10-22 |
4 |
AS |
$189.00 |
$120,582 |
D/D |
(638) |
13,098 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP and CMO |
• – – |
2019-10-30 |
4 |
AS |
$199.00 |
$608,343 |
D/D |
(3,057) |
13,098 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP and CMO |
• – – |
2019-10-30 |
4 |
OE |
$155.57 |
$475,577 |
D/D |
3,057 |
16,155 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP and CMO |
• – – |
2019-11-08 |
4 |
AS |
$199.00 |
$101,291 |
D/D |
(509) |
13,098 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP and CMO |
• – – |
2019-11-08 |
4 |
OE |
$155.57 |
$79,185 |
D/D |
509 |
13,607 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP and CMO |
• – – |
2019-11-15 |
4 |
AS |
$205.95 |
$12,563 |
D/D |
(61) |
13,098 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP and CMO |
• – – |
2019-11-25 |
4 |
OE |
$187.53 |
$879,891 |
D/D |
4,692 |
17,790 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP and CMO |
• – – |
2019-11-25 |
4 |
AS |
$219.37 |
$1,029,284 |
D/D |
(4,692) |
13,098 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP and CMO |
• – – |
2020-02-05 |
4 |
A |
$0.00 |
$0 |
D/D |
22,187 |
35,285 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP and CMO |
• – – |
2020-02-06 |
4 |
AS |
$238.76 |
$496,600 |
D/D |
(2,074) |
35,285 |
0 |
% |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP and CMO |
• – – |
2020-02-06 |
4 |
OE |
$155.57 |
$372,638 |
D/D |
2,074 |
37,359 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP and CMO |
• • – |
2020-02-17 |
4 |
D |
$241.50 |
$227,976 |
D/D |
(944) |
34,341 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP and CMO |
• • – |
2020-02-18 |
4 |
AS |
$241.71 |
$288,070 |
D/D |
(1,183) |
33,158 |
0 |
% |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP and CMO |
• • – |
2020-02-24 |
4 |
D |
$239.23 |
$693,289 |
D/D |
(2,898) |
30,260 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP and CMO |
• • – |
2020-02-25 |
4 |
AS |
$229.72 |
$848,371 |
D/D |
(3,634) |
26,626 |
0 |
% |
|
| VRTX |
Vertex Pharmaceuticals In... |
CEO & President |
• • – |
2020-05-06 |
4 |
AS |
$270.35 |
$565,882 |
D/D |
(2,074) |
26,626 |
0 |
% |
|
| VRTX |
Vertex Pharmaceuticals In... |
CEO & President |
• • – |
2020-05-06 |
4 |
OE |
$155.57 |
$372,638 |
D/D |
2,074 |
28,700 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
CEO & President |
• • – |
2020-05-15 |
4 |
AS |
$274.37 |
$28,132 |
D/D |
(99) |
26,626 |
0 |
% |
|
| VRTX |
Vertex Pharmaceuticals In... |
CEO & President |
• • – |
2020-08-06 |
4 |
AS |
$269.11 |
$562,205 |
D/D |
(2,073) |
26,626 |
0 |
% |
|
55 Records found
|
|
Page 1 of 3 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
